Evidence map›Paper›PMID 30514397›Full record

ArticleActa neuropathologica communications2018

Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.

Kohei Fukuoka, Yonehiro Kanemura, Tomoko Shofuda, Shintaro Fukushima, Satoshi Yamashita, Daichi Narushima, Mamoru Kato, Mai Honda-Kitahara, Hitoshi Ichikawa, Takashi Kohno and 59 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 2 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. A brief history of ependymoma.Neuro-oncology · 2026
    Review
  9. CNS Tumor with BCOR/BCORL1 Fusion: A Rare Tumor Entity.International journal of molecular sciences · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

69 authors at 20 institutions in 3 countries.

Kohei FukuokaDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yonehiro KanemuraDepartment of Biomedical Research and Innovation, Institute for Clinical Research, Osaka National Hospital, National Hospital Organization|, Osaka, Japan.
Tomoko ShofudaDepartment of Biomedical Research and Innovation, Institute for Clinical Research, Osaka National Hospital, National Hospital Organization|, Osaka, Japan.
Shintaro FukushimaDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Satoshi YamashitaDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Daichi NarushimaDepartment of Bioinformatics, National Cancer Center Research Institute, Tokyo, Japan.
Mamoru KatoDepartment of Bioinformatics, National Cancer Center Research Institute, Tokyo, Japan.
Mai Honda-KitaharaDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hitoshi IchikawaDepartment of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Takashi KohnoDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
Atsushi SasakiDepartment of Pathology, Saitama Medical University, Saitama, Japan.
Junko HiratoDepartment of Pathology, Gunma University Hospital, Maebashi, Gunma, Japan.
Takanori HiroseDepartment of Diagnostic Pathology, Hyogo Cancer Center, Kobe, Hyogo, Japan.
Takashi KomoriDepartment of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.
Kaishi SatomiDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Akihiko YoshidaDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.
Kai YamasakiDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yoshiko NakanoDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Ai TakadaDepartment of Biomedical Research and Innovation, Institute for Clinical Research, Osaka National Hospital, National Hospital Organization|, Osaka, Japan.
Taishi NakamuraDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hirokazu TakamiDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yuko MatsushitaDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Tomonari SuzukiDepartment of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Hideo NakamuraDepartment of Neurosurgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Keishi MakinoDepartment of Neurosurgery, Faculty of Life Sciences, Kumamoto University Graduate School, Kumamoto, Japan.
Yukihiko SonodaDepartment of Neurosurgery, Yamagata University School of Medicine, Yamagata, Japan.
Ryuta SaitoDepartment of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Teiji TominagaDepartment of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yasuhiro MatsusakaDepartment of Pediatric Neurosurgery, Osaka City General Hospital, Osaka, Japan.
Keiichi KobayashiDepartment of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, Japan.
Motoo NaganeDepartment of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, Japan.
Takuya FurutaDepartment of Neurosurgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Mitsutoshi NakadaDepartment of Neurosurgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Yoshitaka NaritaDepartment of Neurosurgery and Neurooncology, National Cancer Center Hospital, Tokyo, Japan.
Yuichi HiroseDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Shigeo OhbaDepartment of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Akira WadaDepartment of Neurosurgery, Showa University School of Medicine, Tokyo, Japan.
Katsuyoshi ShimizuDepartment of Neurosurgery, Showa University School of Medicine, Tokyo, Japan.
Kazuhiko KurozumiDepartment of Neurological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
Isao DateDepartment of Neurological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
Junya FukaiDepartment of Neurological Surgery, Wakayama Medical University, Wakayama, Japan.
Yousuke MiyairiDepartment of Neurosurgery, Nagano Children's Hospital, Nagano, Japan.
Naoki KagawaDepartment of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Atsufumi KawamuraDepartment of Neurosurgery, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan.
Makiko YoshidaDepartment of Pathology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan.
Namiko NishidaDepartment of Neurosurgery, Tazuke Kofukai Foundation, Medical Research Institute and Kitano Hospital, Osaka, Japan.
Takafumi WatayaDepartment of Neurosurgery, Shizuoka Children's Hospital, Shizuoka, Japan.
Masayoshi YamaokaDepartment of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
Naohiro TsuyuguchiDepartment of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Takehiro UdaDepartment of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Mayu TakahashiDepartment of Neurosurgery, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.
Yoshiteru NakanoDepartment of Neurosurgery, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.
Takuya AkaiDepartment of Neurosurgery, Kanazawa Medical University, Kanazawa, Japan.
Shuichi IzumotoDepartment of Neurosurgery, Faculty of Medicine, Kinki University, Osaka, Japan.
Masahiro NonakaDepartment of Neurosurgery, Kansai Medical University, Hirakata, Osaka, Japan.
Kazuhisa YoshifujiDepartment of Neurosurgery, Hokkaido Medical Center for Child Health and Rehabilitation, Sapporo, Japan.
Yoshinori KodamaDepartment of Pathology and Applied Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Masayuki ManoDepartment of Pathology, Osaka National Hospital, National Hospital Organization, Osaka, Japan.
Tatsuya OzawaDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Vijay RamaswamyDevelopmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Michael D TaylorDevelopmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Toshikazu UshijimaDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Soichiro ShibuiDepartment of Neurosurgery, Teikyo University Hospital, Mizonokuchi, Kanagawa, Japan.
Mami YamasakiDepartment of Pediatric Neurosurgery, Takatsuki General Hospital, Takatsuki, Osaka, Japan.
Hajime AraiDepartment of Neurosurgery, Juntendo University, Tokyo, Japan.
Hiroaki SakamotoDepartment of Pediatric Neurosurgery, Osaka City General Hospital, Osaka, Japan.
Ryo NishikawaDepartment of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Koichi IchimuraDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. kichimur@ncc.go.jp.
Japan Pediatric Molecular Neuro-Oncology Group (JPMNG)
Osaka National Hospital · JPHospital for Sick Children · CAKanazawa University · JPKobe Children's Hospital · JPNational Cancer Centre Japan · JPSaitama Medical University · JPShowa University · JPUniversity of Occupational and Environmental Health Japan · JPFujita Health University · JPJikei University School of Medicine · JPJuntendo University · JPKanazawa Medical University · JPKansai Medical University · JPKurume University · JPKyorin University · JPKyoto Prefectural University of Medicine · JPOkayama University · JPOsaka City General Hospital · JPTeikyo University Hospital · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extensive molecular analyses of ependymal tumors have revealed that supratentorial and posterior fossa ependymomas have distinct molecular profiles and are likely to be different diseases. The presence of C11orf95-RELA fusion genes in a subset of supratentorial ependymomas (ST-EPN) indicated the existence of molecular subgroups. However, the pathogenesis of RELA fusion-negative ependymomas remains elusive. To investigate the molecular pathogenesis of these tumors and validate the molecular classification of ependymal tumors, we conducted thorough molecular analyses of 113 locally diagnosed ependymal tumors from 107 patients in the Japan Pediatric Molecular Neuro-Oncology Group. All tumors were histopathologically reviewed and 12 tumors were re-classified as non-ependymomas. A combination of RT-PCR, FISH, and RNA sequencing identified RELA fusion in 19 of 29 histologically verified ST-EPN cases, whereas another case was diagnosed as ependymoma RELA fusion-positive via the methylation classifier (68.9%). Among the 9 RELA fusion-negative ST-EPN cases, either the YAP1 fusion, BCOR tandem duplication, EP300-BCORL1 fusion, or FOXO1-STK24 fusion was detected in single cases. Methylation classification did not identify a consistent molecular class within this group. Genome-wide methylation profiling successfully sub-classified posterior fossa ependymoma (PF-EPN) into PF-EPN-A (PFA) and PF-EPN-B (PFB). A multivariate analysis using Cox regression confirmed that PFA was the sole molecular marker which was independently associated with patient survival. A clinically applicable pyrosequencing assay was developed to determine the PFB subgroup with 100% specificity using the methylation status of 3 genes, CRIP1, DRD4 and LBX2. Our results emphasized the significance of molecular classification in the diagnosis of ependymomas. RELA fusion-negative ST-EPN appear to be a heterogeneous group of tumors that do not fall into any of the existing molecular subgroups and are unlikely to form a single category.

Indexed as

AdolescentAdultAgedCarrier ProteinsCentral Nervous System NeoplasmsChildChild, PreschoolDNA MethylationEpendymomaFemaleGenetic TechniquesHistonesHomeodomain ProteinsHumansInfantInfant, NewbornCarrier ProteinsDRD4 protein, humanGRIP1 protein, humanHistonesHomeodomain ProteinsLBX2 protein, humanNerve Tissue ProteinsProteinsReceptors, Dopamine D4RELA protein, humanRNA, MessengerTranscription Factor RelATranscription FactorsZFTA protein, humanEpendymal tumorsFusion geneGene rearrangementMolecular classification

Identifiers

PMID30514397
PMCPMC6278135
OpenAlexW2902612792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.